Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
收藏NIAID Data Ecosystem2026-05-01 收录
官方服务：
资源简介：
KRAS mutant pancreatic cancer models, including KRAS inhibitor resistant models, show exquisite sensitivity to combined pan-ERBB and KRAS targeting, which provides the rationale for testing this drug combination in clinical trials.
创建时间：
2023-06-01
